Repligen (NASDAQ:RGEN) Posts Earnings Results, Misses Estimates By $0.01 EPS

Repligen (NASDAQ:RGEN - Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01), Briefing.com reports. The firm had revenue of $151.31 million during the quarter, compared to analysts' expectations of $150.06 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business's revenue was down 17.1% on a year-over-year basis. During the same quarter last year, the business earned $0.64 EPS. Repligen updated its FY24 guidance to $1.42-1.49 EPS and its FY 2024 guidance to 1.420-1.490 EPS.

Repligen Price Performance

Shares of NASDAQ:RGEN traded up $7.95 during trading on Thursday, reaching $166.31. 848,499 shares of the company's stock traded hands, compared to its average volume of 542,138. The firm has a market cap of $9.29 billion, a PE ratio of 230.99, a P/E/G ratio of 5.38 and a beta of 1.03. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a 50-day simple moving average of $181.40 and a 200-day simple moving average of $173.80. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26.

Insider Activity at Repligen

In other Repligen news, COO James Bylund sold 4,373 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now directly owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Repligen news, COO James Bylund sold 4,373 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now directly owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RGEN has been the subject of a number of research analyst reports. KeyCorp raised their target price on Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. cut their price target on Repligen from $230.00 to $200.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, Stifel Nicolaus increased their price target on Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $195.70.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.